Compare ARBB & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBB | IMNN |
|---|---|---|
| Founded | 1997 | 1982 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 12.5M |
| IPO Year | 2023 | 1985 |
| Metric | ARBB | IMNN |
|---|---|---|
| Price | $5.51 | $3.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $20.00 | ★ $182.61 |
| AVG Volume (30 Days) | 26.2K | ★ 41.6K |
| Earning Date | 11-03-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,842,655.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 239.12 | N/A |
| 52 Week Low | $3.92 | $2.99 |
| 52 Week High | $18.60 | $41.22 |
| Indicator | ARBB | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 32.98 |
| Support Level | $5.72 | $3.28 |
| Resistance Level | $7.34 | $3.89 |
| Average True Range (ATR) | 0.40 | 0.20 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 2.86 | 2.38 |
ARB IOT Group Ltd is a provider of complete solutions to the clients for the integration of Internet of Things (IoT) systems and devices from designing to project deployment. The company offers a wide range of IoT systems as well as provides customers with a substantial range of services such as system integration and system support services. It delivers solutions like designing, installation, testing and commissioning of various IoT systems and devices as well as integration of automated systems, including installation of wire and wireless and mechatronic works. The company operates in two reportable segments: (i) the provision of hardware and software of IoT solutions and (ii) Investment holding and others. The majority of revenue is generated from the IoT solutions segment.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).